Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Anika Therapeutics (ANIK) over the last 11 years, with Q3 2025 value amounting to $14.4 million.

  • Anika Therapeutics' Shares Outstanding (Diluted Average) fell 236.98% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 236.98%. This contributed to the annual value of $15.4 million for FY2015, which is 49.09% up from last year.
  • Per Anika Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $14.4 million for Q3 2025, which was down 236.98% from $14.3 million recorded in Q1 2025.
  • Anika Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $14.8 million during Q2 2024, with a 5-year trough of $14.3 million in Q1 2025.
  • For the 4-year period, Anika Therapeutics' Shares Outstanding (Diluted Average) averaged around $14.6 million, with its median value being $14.7 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 129.27% in 2023, then tumbled by 272.83% in 2025.
  • Quarter analysis of 4 years shows Anika Therapeutics' Shares Outstanding (Diluted Average) stood at $14.6 million in 2022, then rose by 0.38% to $14.7 million in 2023, then grew by 0.75% to $14.8 million in 2024, then decreased by 2.37% to $14.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $14.4 million for Q3 2025, versus $14.3 million for Q1 2025 and $14.8 million for Q3 2024.